Anticoagulants: A Review of the Pharmacology, Dosing, and Complications
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
Abstract
Anticoagulants remain the primary strategy for the prevention and treatment of thrombosis. Unfractionated heparin, low molecular weight heparin, fondaparinux, and warfarin have been studied and employed extensively with direct thrombin inhibitors typically reserved for patients with complications or those requiring intervention. Novel oral anticoagulants have emerged from clinical development and are expected to replace older agents with their ease of use and more favorable pharmacodynamic profiles. Hemorrhage is the main concerning adverse event with all anticoagulants. With their ubiquitous use, it becomes important for clinicians to have a sound understanding of anticoagulant pharmacology, dosing, and toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215 · cited 1×
“0) in patients with non-valvular AF [75].”
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Writing Committee Members, Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R., Green, L. A., Hand, M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., et al. (2004) · Circulation · doi:10.1161/01.cir.0000134791.68010.fa · Cited by 8,356
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
WRITING COMMITTEE MEMBERS*, O’Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., et al. (2013) · Circulation · doi:10.1161/cir.0b013e3182742cf6 · Cited by 4,725
Braunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D., Kupersmith, J., Levin, T. N., et al. (2000) · Circulation · doi:10.1161/01.cir.102.10.1193 · Cited by 4,487
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Kahn (2012) · doi:10.1378/chest.11-2296 · Cited by 2,693
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353 · cited 18×
“In the EINSTEIN-Extension trial, rivaroxaban 20 mg daily extended for an additional 6–12 months significantly reduced recurrent VTE without an increase in major or clinically relevant non-major bleeding when compared with placebo.”
BackgroundInfluentialPrevention of VTE in Nonorthopedic Surgical Patients
Gould, M. K., Garcia, D. A., Wren, S. M., Karanicolas, P. J., Arcelus, J. I., Heit, J. A., & Samama, C. M. (2012) · Chest · doi:10.1378/chest.11-2297 · Cited by 2,131
Emergency Hospitalizations for Adverse Drug Events in Older Americans
Budnitz, D. S., Lovegrove, M. C., Shehab, N., & Richards, C. L. (2011) · New England Journal of Medicine · doi:10.1056/nejmsa1103053 · Cited by 1,820 · cited 1×
“In older patients presenting to an Emergency Department with a warfarin adverse drug event, about half required hospitalization [1].”
Background2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.018 · Cited by 1,772
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809329 · Cited by 1,577
Weitz, J. I. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709043371007 · Cited by 1,533
Ageno, W., Gallus, A. S., Wittkowsky, A., Crowther, M., Hylek, E. M., & Palareti, G. (2012) · Chest · doi:10.1378/chest.11-2292 · Cited by 1,503
Horlocker, T. T., Wedel, D. J., Rowlingson, J. C., Enneking, F. K., Kopp, S. L., Benzon, H. T., Brown, D. L., Heit, J. A., Mulroy, M. F., Rosenquist, R. W., et al. (2010) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0b013e3181c15c70 · Cited by 1,501 · cited 1×
“Indwelling catheters should be removed 2–4 h after discontinuation of the UFH infusion and only after the patient’s coagulation status has been assessed [22].”
BackgroundRivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., Bandel, T. J., Beckmann, H., Muehlhofer, E., Misselwitz, F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800374 · Cited by 1,433 · cited 1×
“The orthopedic surgery program compared rivaroxaban to enoxaparin for VTE prevention in patients undergoing total hip and total knee arthroplasty [76–79].”
MethodEffect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose
Rieder, M. J., Reiner, A. P., Gage, B. F., Nickerson, D. A., Eby, C. S., McLeod, H. L., Blough, D. K., Thummel, K. E., Veenstra, D. L., & Rettie, A. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044503 · Cited by 1,399
Eerenberg, E. S., Kamphuisen, P. W., Sijpkens, M. K., Meijers, J. C., Buller, H. R., & Levi, M. (2011) · Circulation · doi:10.1161/circulationaha.111.029017 · Cited by 1,361
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty
Lassen, M. R., Ageno, W., Borris, L. C., Lieberman, J. R., Rosencher, N., Bandel, T. J., Misselwitz, F., & Turpie, A. G. G. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa076016 · Cited by 1,295 · cited 1×
“The orthopedic surgery program compared rivaroxaban to enoxaparin for VTE prevention in patients undergoing total hip and total knee arthroplasty [76–79].”
MethodEvidence-Based Management of Anticoagulant Therapy
Holbrook, A., Schulman, S., Witt, D. M., Vandvik, P. O., Fish, J., Kovacs, M. J., Svensson, P. J., Veenstra, D. L., Crowther, M., & Guyatt, G. H. (2012) · Chest · doi:10.1378/chest.11-2295 · Cited by 1,269
Institute for Safe Medication Practices
Cohen, M. R. (2002) · Encyclopedia of Clinical Pharmacy · doi:10.3109/9780824706081.079 · Cited by 1,205
Garcia, D. A., Baglin, T. P., Weitz, J. I., & Samama, M. M. (2012) · Chest · doi:10.1378/chest.11-2291 · Cited by 1,091
2012 Writing Committee Members, Jneid, H., Anderson, J. L., Wright, R. S., Adams, C. D., Bridges, C. R., Casey, D. E., Ettinger, S. M., Fesmire, F. M., Ganiats, T. G., et al. (2012) · Circulation · doi:10.1161/cir.0b013e318256f1e0 · Cited by 1,090
Self-citationKakkar, A. K., Brenner, B., Dahl, O. E., Eriksson, B. I., Mouret, P., Muntz, J., Soglian, A. G., Pap, Á. F., Misselwitz, F., & Haas, S. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60880-6 · Cited by 1,070
Antman, E. M., McCabe, C. H., Gurfinkel, E. P., Turpie, A. G. G., Bernink, P. J. L. M., Salein, D., Bayes de Luna, A., Fox, K., Lablanche, J.-M., Radley, D., et al. (1999) · Circulation · doi:10.1161/01.cir.100.15.1593 · Cited by 1,052
Higashi, M. K. (2002) · JAMA · doi:10.1001/jama.287.13.1690 · Cited by 1,048
Treatment and Prevention of Heparin-Induced Thrombocytopenia
Linkins, L.-A., Dans, A. L., Moores, L. K., Bona, R., Davidson, B. L., Schulman, S., & Crowther, M. (2012) · Chest · doi:10.1378/chest.11-2303 · Cited by 1,018
Turpie, A. G., Lassen, M. R., Davidson, B. L., Bauer, K. A., Gent, M., Kwong, L. M., Cushner, F. D., Lotke, P. A., Berkowitz, S. D., Bandel, T. J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60734-0 · Cited by 981
Temporal Aspects of Heparin-Induced Thrombocytopenia
Warkentin, T. E., & Kelton, J. G. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104263441704 · Cited by 977 · cited 5×
“Bivalirudin is indicated for use as an anticoagulant in the treatment of patients with moderate to high-risk ACS, Table 5 Pharmacokinetic and pharmacodynamic properties of DTIs Drugs Indications Dosing, timing, duration Monitoring Precautions Bivalirudin (AngiomaxTM) PCI (with or without glycoprotein IIB/IIIA inhibito…”
BackgroundInfluential(2003) · New England Journal of Medicine · doi:10.1056/nejmoa035451 · Cited by 887
Martel, N., Lee, J., & Wells, P. S. (2005) · Blood · doi:10.1182/blood-2005-04-1546 · Cited by 875 · cited 1×
“The incidence of HIT is approximately one-tenth lower with LMWH than with UFH [37].”
BackgroundCohen, A. T., Davidson, B. L., Gallus, A. S., Lassen, M. R., Prins, M. H., Tomkowski, W., Turpie, A. G. G., Egberts, J. F. M., & Lensing, A. W. A. (2006) · BMJ · doi:10.1136/bmj.38733.466748.7c · Cited by 857
Warfarin, Aspirin, or Both after Myocardial Infarction
Hurlen, M., Abdelnoor, M., Smith, P., Erikssen, J., & Arnesen, H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020496 · Cited by 846
The Perioperative Management of Antithrombotic Therapy
Douketis, J. D., Berger, P. B., Dunn, A. S., Jaffer, A. K., Spyropoulos, A. C., Becker, R. C., & Ansell, J. (2008) · Chest · doi:10.1378/chest.08-0675 · Cited by 830 · cited 1×
“Therapeutic doses of LMWH should not be restarted for 24 h after a major procedure or after neuraxial anesthesia [19, 32].”
BackgroundTreatment and Prevention of Heparin-Induced Thrombocytopenia
Warkentin, T. E., Greinacher, A., Koster, A., & Lincoff, A. M. (2008) · Chest · doi:10.1378/chest.08-0677 · Cited by 816
Management of Anticoagulation before and after Elective Surgery
Kearon, C., & Hirsh, J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199705223362107 · Cited by 812 · cited 2×
“If the aPTT remains elevated, then hourly measurements are advised until the aPTT returns to baseline [19–21].”
BackgroundHylek, E. M., Skates, S. J., Sheehan, M. A., & Singer, D. E. (1996) · New England Journal of Medicine · doi:10.1056/nejm199608223350802 · Cited by 789
Kearon, C., Ginsberg, J. S., Kovacs, M. J., Anderson, D. R., Wells, P., Julian, J. A., MacKinnon, B., Weitz, J. I., Crowther, M. A., Dolan, S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035422 · Cited by 751
Raschke, R. A., Reilly, B. M., Guidry, J. R., Fontana, J. R., & Srinivas, S. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-9-199311010-00002 · Cited by 743 · cited 2×
“UFH dosing nomograms will differ from hospital to hospital due to differences in thromboplastin agents and inter-laboratory standardizations in aPTT measurements [10].”
BackgroundHemorrhagic Complications of Anticoagulant and Thrombolytic Treatment
Schulman, S., Beyth, R. J., Kearon, C., & Levine, M. N. (2008) · Chest · doi:10.1378/chest.08-0674 · Cited by 740
Turpie, A. G. G. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.16.1833 · Cited by 736
Hull, R. D., Raskob, G. E., Hirsh, J., Jay, R. M., Leclerc, J. R., Geerts, W. H., Rosenbloom, D., Sackett, D. L., Anderson, C., Harrison, L., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198610303151801 · Cited by 722
Bauer, K. A., Eriksson, B. I., Lassen, M. R., & Turpie, A. G. G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011099 · Cited by 666
Di Nisio, M., Middeldorp, S., & Büller, H. R. (2005) · New England Journal of Medicine · doi:10.1056/nejmra044440 · Cited by 655
Eriksson, B. I., Bauer, K. A., Lassen, M. R., & Turpie, A. G. G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011100 · Cited by 631
Büller, H. R., Davidson, B. L., Decousus, H., Gallus, A., Gent, M., Piovella, F., Prins, M. H., Raskob, G., Segers, A. E. M., Cariou, R., et al. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-11-200406010-00007 · Cited by 617
Enoxaparin versus Unfractionated Heparin with Fibrinolysis for ST-Elevation Myocardial Infarction
Antman, E. M., Morrow, D. A., McCabe, C. H., Murphy, S. A., Ruda, M., Sadowski, Z., Budaj, A., López-Sendón, J. L., Guneri, S., Jiang, F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060898 · Cited by 609
Medication Use Leading to Emergency Department Visits for Adverse Drug Events in Older Adults
Budnitz, D. S., Shehab, N., Kegler, S. R., & Richards, C. L. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-11-200712040-00006 · Cited by 607 · cited 1×
“Since anticoagulant use enhances the risk for Emergency Department visits by as much as 35-fold [4], clinicians must be familiar with anticoagulants, their pharmacological properties, pharmacodynamics, dosing, monitoring, and toxicity.”
Background(1997) · ACC Current Journal Review · doi:10.1016/s1062-1458(97)83303-x · Cited by 539
Turpie, A. G., Bauer, K. A., Eriksson, B. I., & Lassen, M. R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08648-8 · Cited by 537
Marlu, R., Hodaj, E., Paris, A., Albaladejo, P., Crackowski, J., & Pernod, G. (2012) · Thrombosis and Haemostasis · doi:10.1160/th12-03-0179 · Cited by 501
Meta-Analysis: Low-Molecular-Weight Heparin and Bleeding in Patients with Severe Renal Insufficiency
Lim, W., Dentali, F., Eikelboom, J. W., & Crowther, M. A. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-9-200605020-00011 · Cited by 443 · cited 1×
“Patients with fluctuating renal function or with a creatinine clearance less than 30 mL/min are not candidates for LMWH or fondaparinux due to the risk of accumulation and increased bleeding risk [14].”
BackgroundTrial of Different Intensities of Anticoagulation in Patients with Prosthetic Heart Valves
Saour, J. N., Sieck, J. O., Mamo, L. A. R., & Gallus, A. S. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002153220703 · Cited by 368 · cited 2×
“Patient-specific risk factors are the most important consideration when determining the bleeding risk, including: age, gender, renal failure, low body weight, and excessive alcohol consumption [16–18].”
BackgroundEriksson, B. I. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.11.1337 · Cited by 345
Agnelli, G., Bergqvist, D., Cohen, A. T., Gallus, A. S., & Gent, M. (2005) · British Journal of Surgery · doi:10.1002/bjs.5154 · Cited by 337
Turpie, A. G. G., Robinson, J. G., Doyle, D. J., Mulji, A. S., Mishkel, G. J., Sealey, B. J., Cairns, J. A., Skingley, L., Hirsh, J., & Gent, M. (1989) · New England Journal of Medicine · doi:10.1056/nejm198902093200604 · Cited by 323
Bijsterveld, N. R., Moons, A. H., Boekholdt, S. M., van Aken, B. E., Fennema, H., Peters, R. J. G., Meijers, J. C. M., Büller, H. R., & Levi, M. (2002) · Circulation · doi:10.1161/01.cir.0000038501.87442.02 · Cited by 316 · cited 1×
“While no specific antidote exists for the fondaparinux-related hemorrhage, recombinant activated factor VII (rFVIIa) administration can normalize coagulation times and thrombin generation [51].”
BackgroundGuyatt, G. H., Akl, E. A., Crowther, M. A., Gutterman, D. D., & nemann, H. J. S. (2013) · Cited by 309
Nutescu, E. A., Spinier, S. A., Wittkowsky, A., & Dager, W. E. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l194 · Cited by 289
Bleeding During Antithrombotic Therapy in Patients With Atrial Fibrillation
(1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440040081009 · Cited by 283
Analysis of Randomized Controlled Trials
Peduzzi, P. (2002) · Epidemiologic Reviews · doi:10.1093/epirev/24.1.26 · Cited by 201
A Randomized Trial Comparing 5-mg and 10-mg Warfarin Loading Doses
Crowther, M. A., Ginsberg, J. B., Kearon, C., Harrison, L., Johnson, J., Massicotte, M. P., & Hirsh, J. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.1.46 · Cited by 199 · cited 1×
“Nomogram based dosing is considered safer and more effective at reaching targeting INR goals [64].”
BackgroundHeparin-induced thrombocytopenia in intensive care patients
Selleng, K., Warkentin, T. E., & Greinacher, A. (2007) · Critical Care Medicine · doi:10.1097/01.ccm.0000259538.02375.a5 · Cited by 186 · cited 1×
“The incidence of HITT in critically ill patients ranges from 1 to 5 % and is associated with the development of thrombocytopenia and life-threatening thrombosis in approximately 30–50 % of HIT positive patients [36].”
BackgroundWein, L. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.14.1476 · Cited by 182
Thromboembolic and Bleeding Complications Following St. Jude Medical Valve Replacement
Hering, D., Piper, C., Bergemann, R., Hillenbach, C., Dahm, M., Huth, C., & Horstkotte, D. (2005) · CHEST Journal · doi:10.1378/chest.127.1.53 · Cited by 153
(2012) · CHEST Journal · doi:10.1378/chest.141.4.1129b · Cited by 148
The heparin-protamine interaction. A review.
Carr, J. A., & Silverman, N. (1999) · PubMed · Cited by 146
King, C. S., Holley, A. B., Jackson, J. L., Shorr, A. F., & Moores, L. K. (2007) · CHEST Journal · doi:10.1378/chest.06-1861 · Cited by 139
Aghassarian, M., Drouet, L. O., Sollier, C. B. D., Lacut, K., Heilmann, J., Mottier, D., Bergmann, J., & Mahé, I. (2007) · Thrombosis and Haemostasis · doi:10.1160/th06-09-0513 · Cited by 139 · cited 1×
“1 IU/mL [26, 27].”
Miyares, M. A., & Davis, K. (2012) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp110725 · Cited by 114
Nunnelee, J. D. (2009) · Journal of Vascular Nursing · doi:10.1016/j.jvn.2009.09.001 · Cited by 112
Baetz, B., & Spinler, S. A. (2008) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.28.11.1354 · Cited by 107 · cited 2×
“Furthermore, dabigatran indirectly exerts an anti-platelet effect by reducing thrombin’s impact on promoting platelet activation and aggregation [72].”
BackgroundWarfarin anticoagulation reversal: management of the asymptomatic and bleeding patient
Makris, M., van Veen, J. J., & Maclean, R. (2009) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-009-0412-5 · Cited by 94
Rivaroxaban: An oral direct inhibitor of factor Xa
Gulseth, M. P., Michaud, J. B., & Nutescu, E. A. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070624 · Cited by 93 · cited 1×
“Rivaroxaban is an oral, highly selective, direct, competitive inhibitor of factor Xa [73].”
BackgroundPerioperative Management of Drug Therapy: Clinical Considerations
Stafford‐Smith, M., Muir, H. A., & Hall, R. (1996) · Drugs · doi:10.2165/00003495-199651020-00005 · Cited by 88
Update on heparin: what do we need to know?
Weitz, D. S., & Weitz, J. I. (2009) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-009-0411-6 · Cited by 77 · cited 1×
“Despite these limitations IV administration rapidly achieves therapeutic plasma concentrations that can be effectively monitored and adjusted based on infusion rates [7].”
BackgroundPerioperative Management of Oral Anticoagulation
O'Donnell, M. J., & Kearon, C. (2008) · Cardiology Clinics · doi:10.1016/j.ccl.2007.12.012 · Cited by 31
Efficacy and safety of novel anticoagulants compared with established agents
Rybak, I., Ehle, M., Buckley, L. F., & Fanikos, J. R. (2011) · Therapeutic Advances in Hematology · doi:10.1177/2040620711408489 · Cited by 15
Self-citationManaging Complications of Anticoagulant Therapy
Smythe, M. A., Dager, W. E., & Patel‐Shori, N. M. (2004) · Journal of Pharmacy Practice · doi:10.1177/0897190004271776 · Cited by 1 · cited 1×
“Fondaparinux reversal is further complicated by its prolonged half-life [50].”
Background
Cited by
Delost, M. D., Smith, D. T., Anderson, B. J., & Njardarson, J. T. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00876 · Cited by 409
Metadata
- Authors
- Alquwaizani, M., Buckley, L., Adams, C., & Fanikos, J.
- Venue
- Current Emergency and Hospital Medicine Reports
- Published
- 2013-04-21
- Volume
- 1
- Issue
- 2
- Pages
- 83-97
- ISSN
- 2167-4884 (ISSN-L)
- OpenAlex
- W2036385193
- Cited by
- 201
- References
- 82
- FWCI
- 7.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.